RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Together with local healthcare providers, CCT will facilitate clinical trials for the AZD1222 COVID-19 vaccine.
CCT is recruiting eligible study participants who are 18-85 years old, not pregnant, in good general health and have not been previously diagnosed with COVID-19.
This study compares an investigational vaccine against a placebo to see if the vaccine can prevent COVID-19 and will take place in Phoenix, Arizona.
In apparent response to the news that Pfizer (NYSE:PFE) and BioNTech’s (NASDAQ:BNTX) COVID-19 vaccine candidate BNT162b2 requires storage at a frigid minus 94 degrees Fahrenheit, CureVac (NASDAQ:CVAC) announces that its candidate, CVnCoV, is stable for at least three months at +41 degrees Fahrenheit (+5 Celsius) which is standard refrigerator temperature. It is also stable for up to 24 hours at room temp in a ready-to-use setting.
CVnCoV, an mRNA vaccine, is currently being tested in a Phase 1 study in 284 healthy adult volunteers and in a Phase 2 trial in 691 healthy adults (one and two doses). A large-scale pivotal trial, required to support an EUA application, has not even begun.
Pfizer and BioNTech are weeks away from an EUA application in the U.S. Approval may happen as early as year-end.
Shares up 4% premarket on light volume. PFE and BNTX are both down 1%, also on light volume.
Under the terms of agreement, the Company will offer Truverra-branded medical cannabis products through the Medical Cannabis’ online sales platform accessible to patients across Canada.
“We are particularly pleased to introduce Truverra to Canadian patients, who will be able to order dried flower, pre-rolls and full-spectrum CBD oil. Included in our offering will be our Jean Guy strain, which is a tribute to the legendary variety offered by the Montreal Compassion Club,” said Beena Goldenberg, President and CEO of Supreme Cannabis.
Organicell (OTCPK:BPSR) announces that several participants have been enrolled in its Phase 1/2 clinical trial evaluating Zofin in COVID-19 patients with moderate-to-severe acute respiratory distress syndrome. The subjects have been enrolled and treated at Larkin Hospital in Miami, FL.
It expects to complete the 20-subject study by year-end.
The company says Zofin (formerly Organicell Flow) is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs without the addition or combination of any other substance or diluent. It contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from perinatal tissues.
ElectroCore (NASDAQ:ECOR): Q3 GAAP EPS of -$0.10 beats by $0.04.
Revenue of $1.08M (+58.8% Y/Y) beats by $0.07M.